Table 1 Baseline clinical characteristics

Age at inclusion (years)

Median (range)

59 (20–81)

Gender

Male

38

63

Female

22

37

ECOG PS

0

28

47

1

32

53

T stage

T2

3

6

T3

24

45

T4a

16

30

T4b

6

11

Tx

4

8

N stage

N0

11

21

N1

17

33

N2a

15

29

N2b

4

8

Nx

5

10

Metastatic sites^b

Liver

46

77

Lung

45

52

Peritoneal cavity

14

23

Others

10

17

Number of metastatic sites

1

10

17

2

27

45

3

16

27

 > 3

7

17

Prior treatments

Surgery

49

82

Radiotherapy

19

68

Chemotherapy + TT

58

97

Median N lines (range)

2 (1–5)

Molecular status

PDL1 ≥ 1%

11

18

MSS NA

19

32

pMMR

33

55

MSI-H

8^a

13

KRAS/NRAS

25

42

HER2

3

5

MET

1

2

PI3KCA

1

2

BRAF

6

10

Atezolizumab

median N cycles (range)

4 (1–94)

SBRT (Gy)

Median dose (range)

45 (21–45)

Irradiated sites

Lung

30

56

Liver

18

33

Others

8

13